文献速递中医内科中医儿科中药与中成药合理使用

玉丹通方通过抑制钙离子内流阻断NLRP3炎症小体活化治疗胆汁淤积性肝病

Yu Dan Tong Formula inhibits NLRP3 inflammasome activation by suppressing Ca²⁺ influx in treating cholestatic liver disease.
PubMed 文献 · Phytomedicine · 2026-02-14

该研究探讨玉丹通方(YDTF)治疗胆汁淤积性肝病(CLD)的药理机制是否与抑制NLRP3炎症小体活化有关。在LPS诱导的系统性炎症小鼠模型和ANIT诱导的CLD小鼠模型中,YDTF剂量依赖性地抑制NLRP3活化,减少钙离子内流及ASC寡聚化,并减轻肝损伤和炎症反应。提示抑制NLRP3活化可能是YDTF治疗CLD的关键药理策略。

要点

  • 玉丹通方可剂量依赖性地广谱抑制NLRP3炎症小体活化。
  • 机制涉及抑制钙离子内流,进而减少ASC寡聚化及炎症小体组装。
  • 在ANIT诱导的CLD小鼠中,玉丹通方改善肝功能并减轻肝损伤。

核心结论

  • 玉丹通方通过抑制钙离子内流阻断NLRP3炎症小体活化,从而减轻ANIT诱导的CLD小鼠肝损伤。
  • 抑制NLRP3活化可能是治疗CLD的重要药理策略,玉丹通方或对其它NLRP3炎症小体驱动疾病有益。

研究设计与样本

  • 基础实验研究,使用LPS诱导的C57BL/6小鼠系统性炎症模型和ANIT诱导的C57BL/6小鼠CLD模型。

主要发现

  • 玉丹通方以剂量依赖方式广谱抑制经典与非经典NLRP3激动剂(包括TCDCA)激活巨噬细胞炎症小体。
  • 玉丹通方抑制钙离子内流,减少ASC寡聚化及后续炎症小体组装与活化。
  • 在ANIT诱导的CLD小鼠中,玉丹通方有效抑制NLRP3炎症小体活化并减轻炎症反应程度。
  • 玉丹通方改善异常肝功能并减轻肝损伤。

临床怎么用

  • 对于NLRP3炎症小体相关胆汁淤积性肝病,玉丹通方可能通过抑制钙离子内流和NLRP3活化发挥保肝作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cholestatic liver disease (CLD) is a common disorder characterized by impaired bile flow that results in liver injury and fibrosis. However, current therapeutic options for CLD are limited and ineffective. Yu Dan Tong Formula (YDTF), a formulated Traditional Chinese Medicine (TCM), has been routinely used for over 50 years at Beijing Children's Hospital for the treatment of CLD in children. We previously found that YDTF can reduce jaundice and alleviate liver injury. However, the pharmacological mechanisms underlying the effects of YDTF on CLD remain unclear. PURPOSE: This study aimed to investigate the pharmacological mechanisms of YDTF in the treatment of CLD, with a focus on NLRP3 inflammasome activation. METHODS: Macrophage inflammasomes were activated by classical and non-classical NLRP3 agonists, including taurochenodeoxycholic acid (TCDCA). The effects of YDTF on inflammasome activation and inflammatory responses were assessed in an lipopolysaccharide (LPS)-induced murine model of systemic inflammation in C57BL/6 mice, and the underlying mechanisms were evaluated. The effects of YDTF on NLRP3 activation and its therapeutic potential in CLD were explored using an α-naphthylisothiocyanate (ANIT)-induced CLD model in C57BL/6 mice RESULTS: YDTF inhibited NLRP3 activation in a dose-dependent manner with broad-spectrum inhibitory effects. Mechanistically, YDTF inhibited Ca²⁺ influx, thereby inhibiting apoptosis-associated speck-like protein (ASC) oligomerization, and subsequent inflammasome assembly and activation. In the ANIT-induced CLD mouse model, YDTF effectively suppressed NLRP3 inflammasome activation and reduced the magnitude of the inflammatory response. Furthermore, YDTF alleviated abnormal liver function and resolved liver injury. CONCLUSIONS: YDTF effectively inhibited NLRP3 activation by inhibiting Ca²⁺ influx and significantly alleviated liver injury in the ANIT-induced CLD model. The inhibition of NLRP3 activation could represent a critical pharmacological strategy for the treatment of CLD. Additionally, our results suggest that YDTF may be beneficial in treating other NLRP3 inflammasome-driven diseases.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Yang N, Guo Y, Wang X, et al. Yu Dan Tong Formula inhibits NLRP3 inflammasome activation by suppressing Ca²⁺ influx in treating cholestatic liver disease. Phytomedicine. 2026. PMID: 41747589. doi:10.1016/j.phymed.2026.157947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。